Amylyx Pharmaceuticals Advances AMX0318 as Long-Acting GLP-1 Receptor Antagonist for Rare Diseases
I'm PortAI, I can summarize articles.
Amylyx Pharmaceuticals Inc. has nominated AMX0318 as a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases. The candidate has shown strong preclinical results in stability, solubility, potency, and tolerability. The company plans to move AMX0318 into IND-enabling studies later this year, with an IND submission expected in 2027, pending successful study outcomes. Further development is ongoing, and results have not yet been presented.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments